publication venue for
- New insights into the cost-effectiveness of lung cancer treatment 1999
- Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma. 37:176-183. 2023
- Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma. 37:175-184. 2023
- Bevacizumab in advanced lung cancer: in search of the right drug for the right patient.. 24:1223-1226. 2010
- BDNF/TrkB Content and Interaction with Gastrin-Releasing Peptide Receptor Blockade in Colorectal Cancer. 79:430-439. 2010
- Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program. 78:340-347. 2010
- Emerging role of HIFU as a noninvasive ablative method to treat localized prostate cancer - The Barqawi/Crawford article reviewed. 22:129-+. 2008
- High-intensity focused ultrasound: A Canadian perspective. 22. 2008
- Thirty years later: We've only just begun. 20:1663-+. 2006
- Thromboembolic complications of malignancy: Part 1: Risk. Commentary. 19. 2005
- The Horiike/Saijo article reviewed. 19:55-56. 2005
- Thrombo-embolic complications of malignancy - Part 2: Management - The Linenberger/Wittkowsky article reviewed. 19:1087-1088. 2005
- Small-cell lung cancer: Current therapy and novel agents - The Horiike/Saijo article reviewed. 19:55-56. 2005
- Breast cancer: New radiation treatment options - The Arthur/Morris/Vicini article reviewed. 18:1637-1638. 2004
- The Arthur/Morris/Vicini article reviewed. 18:1637-1638. 2004
- The Clinical Significance of Tenascin-C Splice Variant Expression in Chondrosarcoma. 61:306-314. 2001
- The McCarthy/Swain article reviewed. 14:1284-+. 2000
- Management of venous thromboembolism in cancer patients.. 14:409-421. 2000
- Canadian Oncologists and Clinical Practice Guidelines: A National Survey of Attitudes and Reported Use. 59:283-290. 2000
- New insights into the cost-effectiveness of lung cancer treatment. 13:16-21. 1999
- A Comparison with Standard Chemotherapy and Best Supportive Care: Cost-Effectiveness of Vinorelbine Alone or Vinorelbine Plus Cisplatin for Stage IV NSCLC. 12:18-25. 1998
- Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC. 12:18-26. 1998
- Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC.. 12:18-25. 1998
- A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.. 11:24-29. 1997
- The Ontario Cancer Treatment Practice Guidelines Initiative.. 10:19-22. 1996
- The cost of managing lung cancer in Canada.. 9:147-153. 1995
- Phase II Evaluation of Lonidamine in Patients with Advanced Malignancy. 41:69-77. 1984
- Hormonal Effects upon the Rate of Proliferation of the Murine Plasmacytoma MOPC 315. 37:411-417. 1980